Dilate blood vessels and improve microcirculation; activate plasmin and reduce blood viscosity; activate phospholipase A2, prevent platelet aggregation, and prevent thrombosis, etc.

Extract from the above information

This product directly acts on the endogenous fibrinolytic system and can catalyze the cleavage of plasminogen into plasmin, which can not only degrade fibrin clots, but also degrade fibrinogen, coagulation factor V and coagulation factor VIII in the blood circulation, thereby exerting a thrombolytic effect. This product has a fast onset and good effect on newly formed thrombi. This product can also increase the activity of vascular ADP enzyme, inhibit ADP-induced platelet aggregation, and prevent thrombosis. This product shows a significant correlation between the thrombolytic effect and the drug dosage and the time window of administration.

This product acts directly on the endogenous fibrinolytic system and can catalyze the cleavage of plasminogen into plasmin, which can not only degrade fibrin clots, but also degrade fibrinogen, coagulation factor V and coagulation factor VIII in the blood circulation, thereby exerting a thrombolytic effect. This product has a fast onset and good effect on newly formed thrombi. This product can also increase the activity of vascular ADP enzyme, inhibit ADP-induced platelet aggregation, and prevent thrombosis. After intravenous infusion of this product, the activity of plasmin in the patient's body is significantly increased; after a few hours of discontinuation of the drug, the activity of plasmin returns to the original level. However, the decrease in plasma fibrin or fibrinogen levels and the increase in their degradation products can last for 12-24 hours. This product shows a significant correlation between the thrombolytic effect and the drug dose and the time window of administration.

It acts directly on the endogenous fibrinolytic system and can catalyze the cleavage of plasminogen into plasmin, which can not only degrade fibrin clots, but also degrade fibrinogen, coagulation factor V and coagulation factor VIII in the blood circulation, thereby exerting a thrombolytic effect; it increases the activity of vascular ADP enzyme, inhibits ADP-induced platelet aggregation, and prevents thrombosis; after intravenous infusion, it significantly increases the activity of plasmin in the patient's body; it shows a significant correlation between the thrombolytic effect and the drug dosage and the time window of administration; it has very low toxicity, no obvious antigenicity, teratogenicity, carcinogenicity and mutagenicity, and there are rare reports of allergic reactions in clinical use; it may increase the risk of bleeding.